NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 17 04:00PM ET
21.18
Dollar change
+0.65
Percentage change
3.17
%
IndexRUT P/E- EPS (ttm)-2.06 Insider Own0.93% Shs Outstand11.95M Perf Week7.51%
Market Cap253.16M Forward P/E77.02 EPS next Y0.28 Insider Trans-85.26% Shs Float11.84M Perf Month1.34%
Income-23.69M PEG- EPS next Q-0.24 Inst Own60.07% Short Float1.26% Perf Quarter-22.39%
Sales28.49M P/S8.89 EPS this Y69.85% Inst Trans-11.29% Short Ratio3.96 Perf Half Y-26.20%
Book/sh6.85 P/B3.09 EPS next Y155.28% ROA-5.99% Short Interest0.15M Perf Year-13.13%
Cash/sh8.91 P/C2.38 EPS next 5Y- ROE-16.20% 52W Range18.35 - 35.00 Perf YTD-19.41%
Dividend Est.- P/FCF- EPS past 5Y-48.78% ROI-12.51% 52W High-39.49% Beta0.88
Dividend TTM- Quick Ratio5.15 Sales past 5Y96.66% Gross Margin99.24% 52W Low15.41% ATR (14)1.16
Dividend Ex-Date- Current Ratio5.15 EPS Y/Y TTM49.92% Oper. Margin-140.33% RSI (14)54.26 Volatility4.25% 5.61%
Employees13 Debt/Eq1.46 Sales Y/Y TTM498.72% Profit Margin-83.15% Recom1.50 Target Price64.67
Option/ShortYes / Yes LT Debt/Eq1.31 EPS Q/Q75.94% Payout- Rel Volume0.39 Prev Close20.53
Sales Surprise-0.53% EPS Surprise86.09% Sales Q/Q375.40% EarningsMar 17 AMC Avg Volume37.65K Price21.18
SMA204.88% SMA50-3.53% SMA200-19.80% Trades Volume14,845 Change3.17%
Date Action Analyst Rating Change Price Target Change
Apr-17-25Initiated The Benchmark Company Buy $35
Apr-29-24Initiated Leerink Partners Outperform $40
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Apr-14-25 07:30AM
Apr-09-25 09:45AM
Apr-08-25 07:15AM
12:24AM
Apr-02-25 07:30AM
07:30AM Loading…
Mar-20-25 07:30AM
Mar-17-25 04:30PM
Feb-24-25 04:05PM
Feb-04-25 07:30AM
Dec-19-24 07:30AM
Dec-02-24 07:30AM
Nov-11-24 12:00PM
Nov-07-24 09:00AM
07:52AM
07:30AM
08:00AM Loading…
Oct-22-24 08:00AM
08:00AM
Sep-23-24 06:30AM
05:30AM
Sep-04-24 07:30AM
Aug-13-24 08:45AM
07:39AM
07:30AM
Jul-18-24 04:08AM
Jun-21-24 07:54AM
Jun-20-24 07:30AM
Jun-12-24 07:30AM
06:00AM
May-14-24 07:30AM
May-10-24 03:18PM
01:55PM Loading…
May-09-24 01:55PM
08:00AM
07:30AM
May-07-24 10:00AM
Apr-30-24 07:30AM
Apr-25-24 07:30AM
Apr-24-24 09:00AM
Apr-03-24 09:00AM
Mar-21-24 07:30AM
Mar-19-24 04:05PM
Mar-08-24 12:53PM
08:12AM
07:52AM
07:30AM
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
07:30AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
07:30AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
07:30AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
07:30AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
07:30AM
May-03-22 08:15AM
Apr-20-22 08:24AM
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sitko BradleyChief Investment OfficerApr 07 '25Buy24.702,00049,4005,045Apr 09 04:44 PM
LIMBER JOSEPH MDirectorApr 03 '25Buy25.2417,935452,63116,524Apr 07 04:39 PM
LIMBER JOSEPH MDirectorApr 04 '25Buy25.406,822173,29320,000Apr 07 04:39 PM
LIMBER JOSEPH MDirectorApr 07 '25Buy25.605,243134,22110,000Apr 07 04:39 PM
Sitko BradleyChief Investment OfficerMar 31 '25Buy21.041,24526,20111,484Apr 02 04:30 PM
BURNS THOMAS M.SVP, Finance & CFOApr 01 '25Buy25.461,00025,4602,000Apr 02 04:30 PM
Sitko BradleyChief Investment OfficerMar 21 '25Buy23.894,13498,75110,484Mar 25 04:30 PM
BVF PARTNERS L P/IL10% OwnerJan 24 '25Sale26.10500,74213,069,3660Jan 28 05:23 PM
BVF PARTNERS L P/IL10% OwnerJan 24 '25Sale26.10149,9753,914,3480Jan 28 05:23 PM
Sitko BradleyChief Investment OfficerJan 08 '25Buy25.603138,013313Jan 10 04:30 PM
Sitko BradleyChief Investment OfficerJan 08 '25Buy25.702325,96282Jan 10 04:30 PM
Sitko BradleyChief Investment OfficerDec 31 '24Buy25.903007,7709,150Jan 03 04:30 PM
BURNS THOMAS M.SVP, Finance & CFONov 11 '24Option Exercise0.0017,773024,328Nov 13 06:55 PM
BURNS THOMAS M.SVP, Finance & CFONov 13 '24Sale29.949,775292,66414,553Nov 13 06:55 PM
Hughes OwenChief Executive OfficerNov 11 '24Option Exercise0.0053,360056,860Nov 13 06:55 PM
Hughes OwenChief Executive OfficerNov 13 '24Sale29.9521,881655,33634,979Nov 13 06:55 PM